REMARKS

Applicants enclose the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The specification has been amended to provide SEQ ID NOS for the sequences disclosed therein. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: July 2, 2001

Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

PATENT

Attorney Docket No.: 10017.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al. Serial No.: 09/784,554

Confirmation No: 5362 Group Art Unit: 1651

Filed: February 16, 2001 Examiner: To be assigned

For: Family 44 Xyloglucanases

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Commissioner for Patents
Washington, DC 20231

Sir:

Below is a marked-up version of the amendments made in the accompanying amendment.

IN THE SPECIFICATION:

The paragraph on page 62, lines 3-6 has been amended as follows:

The two PCR primers used have the following sequences:

LWN5494 5′-GTCGCCGGGGCGGCCGCTATCAATTGGTAACTGTATCTCAGC -3′ (SEQ ID NO:7)

LWN5495 5′-GTCGCCCGGGAGCTCTGATCAGGTACCAAGCTTGTCGACCTGCAGAA TGAGGCAGCAAGAAGAT -3′ (SEQ ID NO:8)

The paragraphs on page 62, lines 13-27 have been amended as follows:

This cloning replaces the first amyL promoter cloning with the same promoter but in the opposite direction. The two primers used for PCR amplification have the following sequences:

#LWN5938 5`-GTCGGCGGCCGCTGATCACGTACCAAGCTTGTCGACCTGCAGAATG AGGCAGCAAGAAGAT -3′ (SEQ ID NO:9)

#LWN5939 5`-GTCGGAGCTCTATCAATTGGTAACTGTATCTCAGC -3′ (SEQ ID NO:10)

The plasmid pSJ2670 was digested with the restriction enzymes PstI and BclI and a PCR fragment amplified from a cloned DNA sequence encoding the alkaline amylase SP722 (International Patent Application published as WO95/26397 which is hereby incorporated by reference) was digested with PstI and BclI and inserted to give the plasmid pMOL944. The two primers used for PCR amplification have the following sequence:

#LWN7864 5` -AACAGCTGATCACGACTGATCTTTTAGCTTGGCAC-3´ (SEQ ID NO:11)

#LWN7901 5` -AACTGCAGCCGCGGCACATCATAATGGGACAAATGGG -3´ (SEQ ID NO:12)

The paragraph on page 62, line 35 – page 63, line10 has been amended as follows:

Construction of pPL3143 : The plasmid pMOL944 was digested with SacII and NotI . A PCR fragment generating a terminator was made using the two primers listed below and plasmid pMOL944 as template. This fragment was digested with EagI and SacII and inserted between the SacII and the NotI site in PMOL944 to create the plasmid pPL3143.

Primer 130721:

5' – CGATCGGCCGATAAAAAAACCGGGCGGAAACCGCCCGTCATCTGGCGCGCCT AT-3' (SEQ ID NO:13)

Primer 130722:

5' -- GGCGCATTAACGGAATAAAGGGTGT - 3' (SEQ ID NO:14)

The paragraph on page 67, lines 20-25 has been amended as follows:

The XYG1006 encoding DNA sequence was PCR amplified using the PCR primer set consisting of these two oligo nucleotides:

XYG1006 .upper.PstI

5'-GCATTCTGCAGCAGCGGCTGTGGTTCACGGTCAAACGGC -3' (SEQ ID NO:15)

XYG1006 .lower.AscI

5'-GCTAGGCGCGCCTACACTGGAGACGTGTCATTGCCAGTAG -3' (SEQ ID NO:16)